Clinical Trials
33 trialsNCT07510334 2026-06-05
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Recruiting
NCT02210117 2026-06-01
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04388852 2026-05-20
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06708949 2026-05-14
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07128680 2026-05-11
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07188896 2026-05-01
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05361720 2026-04-27
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04413123 2026-01-21
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05501054 2026-01-14
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03274258 2025-12-03
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT07233668 2025-12-03
IVE in mRCC
Seoul National University Hospital
Phase NA Not yet recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT04495257 2025-10-30
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
Phase 1 Active not recruiting
NCT05148546 2025-09-30
NESCIO
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT06866262 2025-09-09
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT04090710 2025-08-03
CYTOSHRINK
Ontario Clinical Oncology Group (OCOG)
Phase 2 Active not recruiting
NCT03297593 2025-06-06
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT03552380 2024-09-03
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03829111 2024-07-03
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04429321 2024-04-26
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02917772 2022-10-06
TITAN-RCC
AIO-Studien-gGmbH
Phase 2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03177239 2022-02-16
UNISoN
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04134182 2020-12-23
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT03149159 2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
Phase 2 Withdrawn